Newsroom | 86261 results

Sorted by: Latest
Pharmaceutical
-

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025

LYON, France--(BUSINESS WIRE)--MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025...
-

Poxel SA: New Scientific Presentations by Key Opinion Leaders to Further Highlight the Therapeutic Potential of Imeglimin at ADA 2025, the Leading Diabetes Conference

LYON, France--(BUSINESS WIRE)--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, today announces that five presentations in relation to the potential of Imeglimin, marketed under the brand name TWYMEEG® in Japan, will be made at the 85th Scientific Sessio...
-

Chiesi Global Rare Diseases octroie des subventions de recherche visant à faire progresser l’innovation dans le domaine des maladies lysosomales

PARME, Italie--(BUSINESS WIRE)--Chiesi Global Rare Diseases, une unité commerciale de Chiesi Group créée pour proposer des solutions innovantes aux personnes atteintes de maladies rares, a annoncé aujourd’hui les lauréats de son programme de subventions de recherche « Find For Rare ». Cette initiative de bourses de recherche évaluée de manière indépendante et dirigée par des experts vise à améliorer les soins et la prise en charge des patients en récompensant la recherche innovante dans trois m...
-

Chiesi Global Rare Diseases kent onderzoekssubsidies toe om innovatie in lysosomale ziektes te bevorderen

PARMA, Italië--(BUSINESS WIRE)--Chiesi Global Rare Diseases, een bedrijfsonderdeel van de Chiesi Group opgericht om innovatieve oplossingen te leveren voor mensen die een zeldzame aandoening hebben, kondigde vandaag de ontvangers aan van zijn "Find For Rare" onderzoekssubsidieprogramma. Het onafhankelijk beoordeelde, door experts geleide onderzoekssubsidie-initiatief beoogt om de behandeling en de zorg voor patiënten te verbeteren door innovatief onderzoek te erkennen in drie lysosomale ziektes...
-

PharmaJet® and Immuno Cure Sign Agreement for Clinical Development of a Needle-free HIV Therapeutic DNA Vaccine

GOLDEN, Colo.--(BUSINESS WIRE)--Agreement with Immuno Cure adds to PharmaJet's portfolio of global development partnerships with innovative oncology & infectious disease developers....
-

Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)

BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction of urine homogentisic acid (HGA) in adult patients with AKU.1 Launching in July 2025, HARLIKU will be the first and only FDA-approved treatment for AKU,1 an ultra-rare genetic metabolic disorder in which patients have a buildup of HGA that leads to osteoarthritis, ochronosis, and complications in the kidneys, and heart.2 Patients with AKU often d...
-

Quantum-Si to Join Leading Experts from DNAnexus, Olink, and Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration and Standardization

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Join Leading Experts from DNAnexus, Olink, & Northwestern in Upcoming GenomeWeb Webinar on Proteomics Data Integration & Standardization...
-

Lundbeck Advances Leadership in Migraine With New Data at the American Headache Society 67th Annual Scientific Meeting

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck advances leadership in migraine with new data at the American Headache Society 67th Annual Scientific Meeting...
-

Chiesi Global Rare Diseases vergibt Forschungsstipendien zur Förderung von Innovationen bei lysosomalen Erkrankungen

PARMA, Italien--(BUSINESS WIRE)--Chiesi Global Rare Diseases, ein Geschäftsbereich der Chiesi Group, der gegründet wurde, um innovative Lösungen für Menschen mit seltenen Krankheiten anzubieten, gab heute die Preisträger seines Forschungsstipendienprogramms „Find For Rare” bekannt. Die unabhängig bewertete, von Experten geleitete Forschungsstipendieninitiative zielt darauf ab, die Patientenversorgung und -behandlung zu verbessern, indem innovative Forschung zu drei lysosomalen Erkrankungen ausg...
-

Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

ACTON, Mass.--(BUSINESS WIRE)--Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod 5 on Improved Health Outcomes at the American Diabetes Association Conference...